SEC Tracker
Get the app

Entera Bio ENTX

Entera Bio announces 2026 shareholder meeting

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Scheduled for November 24, 2026
  2. Raised $275 million in private placement
  3. Proposals include equity grants for executives

Written from the DEF 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Entera Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Instil Bio TIL public float $83M, Jun 30, 2025
  2. Coherus Oncology CHRS public float $82M, Jun 30, 2025
  3. SAB Biotherapeutics SABS public float $77M, Jun 30, 2025
  4. Vor Biopharma VOR public float $76M, Jun 30, 2025
  5. Jasper Therapeutics JSPR public float $75M, Jun 30, 2025